Formation of Research Management Committee Sample Clauses

Formation of Research Management Committee. The Research Program established by this Agreement shall be overseen by a Research Management Committee composed of an equal number of representatives from each Party (the "Research Management Committee") drawn from the ranks of senior scientists and senior research management of each Party. The total number of RMC members shall be agreed upon by the RMC from time to time. The Parties shall designate their representatives on the RMC within ten (10) days after the Effective Date. The Parties shall notify one another in writing of any change in the membership of the RMC as appropriate to allow for the participation of different research groups within Xxxxxxx and Xxxxx. The Parties shall agree upon the appropriate qualifications for members of the RMC and mechanisms for making substitutions for RMC members. An alternate member designated by a Party may serve temporarily in the absence of a permanent member of the RMC for such Party. Each Party shall designate one of its representatives as a co-chair of the RMC. Each co-chair of the RMC will be responsible for the agenda and the minutes of alternating RMC meetings.
Sample 1Sample 2Sample 3See All (4)
AutoNDA by SimpleDocs
Formation of Research Management Committee. The Research Collaboration shall be managed by the Research Management Committee comprised of an equal number of members appointed by each of Roche Bioscience and Tularik; provided that the size of the Research Management Committee shall not exceed a total of eight members. Either Party may appoint substitute or replacement members of the Research Management Committee to serve as their representatives. The initial members of the Research Management Committee shall be appointed by the Parties within 30 days following the Effective Date. The Research Management Committee shall have the responsibility and authority to: (a) plan and monitor the research; (b) assign tasks and responsibilities under the Research Plan to Tularik and Roche Bioscience; (c) review and modify the Research Plan as it shall deem appropriate to achieve the Parties' objectives of developing commercially successful Products; and (d) nominate Research Compounds for IND-enabling studies (and designate any such Research Compounds as either Roche Bioscience Compounds or Tularik Compounds prior to the commencement of such studies); provided that the Research Management Committee may not take any action in conflict with the express terms of this Agreement.
Sample 1Sample 2Sample 3
Formation of Research Management Committee. 10 3.2 Meetings of Research Management Committee................ 11 3.3 Decision-Making Process.................................. 11 4.
Sample 1Sample 2Sample 3
Formation of Research Management Committee. The Research will be managed by the Research Management Committee comprised of an equal number of members appointed by each of Roche Bioscience and Alanex; provided that the size of the Research Management Committee shall not exceed a total of eight members. Either Party may appoint substitute or replacement members of the Research Management Committee to serve as their representatives. The initial members of the Research Management Committee will be appointed by the Parties within 30 days following the Effective Date. The Research Management Committee shall have the responsibility and authority to: (a) plan and monitor the Research, (b) assign tasks and responsibilities under the Research Plan to Alanex and Roche Bioscience, respectively, subject to the terms and conditions of this Agreement which may not be amended except in accordance with Section 16.11 hereof (c) review and modify the Research Plan, as it shall deem appropriate to achieve the Parties' objectives under this Agreement, subject to the terms and conditions of this Agreement which may not be amended except in accordance with Section 16.11 hereof (d) review data related to Compounds to evaluate whether such Compounds satisfy the Preclinical Development Criteria, and (e) recommend Compounds to Roche Bioscience for selection as Lead Compounds. Notwithstanding the provisions of this Section 3.1, the Research Management Committee shall not have the authority to amend the Preclinical Development Criteria.
Sample 1

Related to Formation of Research Management Committee

  • Joint Development Committee The Parties shall form a joint development committee (the “Joint Development Committee” or “JDC”), made up of an equal number of representatives of Merck and BioLineRx, which shall have responsibility of coordinating all regulatory and other activities under, and pursuant to, this Agreement. Each Party shall designate a project manager (the “Project Manager”) who shall be responsible for implementing and coordinating activities, and facilitating the exchange of information between the Parties, with respect to the Study. Other JDC members will be agreed by both Parties. The JDC shall meet as soon as practicable after the Effective Date and then no less than twice yearly, and more often as reasonably considered necessary at the request of either Party, to provide an update on the progress of the Study. The JDC may meet in person or by means of teleconference, Internet conference, videoconference or other similar communications equipment. Prior to any such meeting, the BioLineRx Project Manager shall provide an update in writing to the Merck Project Manager, which update shall contain information about the overall progress of the Study, recruitment status, interim analysis (if results available), final analysis and other information relevant to the conduct of the Study. In addition to a Project Manager, each Party shall designate an alliance manager (the “Alliance Manager”), who shall endeavor to ensure clear and responsive communication between the Parties and the effective exchange of information, and shall serve as the primary point of contact for any issues arising under this Agreement. The Alliance Managers shall have the right to attend all JDC meetings and may bring to the attention of the JDC any matters or issues either of them reasonably believes should be discussed, and shall have such other responsibilities as the Parties may mutually agree in writing. In the event that an issue arises and the Alliance Managers cannot or do not, after good faith efforts, reach agreement on such issue, the issue shall be elevated to the Head of Clinical Oncology for Merck and the Vice President of Medical Affairs or Business Development for BioLineRx.

  • Development Committee As soon as practicable, the Parties will establish a joint development committee, comprised of at least one (1) and up to two (2) representatives of Omega and at least one (1) and up to two (2) representatives of Acuitas (the “JDC”). One such representative from each Party will be such Party’s Workplan Leader. Each Party may replace its Workplan Leader and other JDC representatives at any time upon written notice to the other Party, provided, however, that each Party shall use reasonable efforts to ensure continuity on the JDC. With the consent of the other Party (which will not be unreasonably withheld, conditioned or delayed), each Party may invite non-voting employees and consultants to attend JDC meetings as necessary, subject to consultant’s agreement to be bound to the same extent as a permitted subcontractor under Section 3.1(i).

  • Collaboration Management Promptly after the Effective Date, each Party will appoint a person who will oversee day-to-day contact between the Parties for all matters related to the management of the Collaboration Activities in between meetings of the JSC and will have such other responsibilities as the Parties may agree in writing after the Effective Date. One person will be designated by Merck (the “Merck Program Director”) and one person will be designated by Moderna (the “Moderna Program Director,”) together will be the “Program Directors”. Each Party may replace its Program Director at any time by notice in writing to the other Party. Any Program Director may designate a substitute to temporarily perform the functions of that Program Director by written notice to the other Party. The initial Program Directors will be: For Moderna: [***] For Merck: [***]

  • Joint Research Committee The Parties hereby establish a committee to facilitate the Research Program as follows:

  • Operating Committee 7.01 To coordinate the operation of their respective generating, transmission and substation facilities, in order that the advantages to be derived hereunder may be realized by the parties hereto to the fullest practicable extent, the parties shall establish a committee of authorized representatives to be known as the Operating Committee. Each of the parties shall designate in writing delivered to the other party, the person who is to act as its representative on said committee (and the person or persons who may serve as alternates whenever such representative is unable to act). Each of such representatives and alternates shall be persons familiar with the generating, transmission, and substation facilities of the system of the party he represents, and each shall be fully authorized (1) to cooperate with the other representative (or alternates) and (2) to determine and agree from time to time, in accordance with this agreement and with any other relevant agreements then in effect between the parties, upon the following:

  • Management Committee The Members shall act collectively through meetings as a "committee of the whole," which is hereby named the "Management Committee." The Management Committee shall conduct its affairs in accordance with the following provisions and the other provisions of this Agreement:

  • Advisory Committee (a) The Partnership shall have a committee (the “Advisory Committee”) consisting of Fund Investors or their representatives or designees selected by the Managing General Partner; provided that no member of the Advisory Committee shall be an Affiliate of the Managing General Partner (or a designee or representative thereof). The Managing General Partner will meet with the Advisory Committee at least semi-annually to consult on various matters concerning the Partnership, including financial statements and appraisals, the status of existing investments and such other matters as the Managing General Partner may determine or any member of the Advisory Committee may reasonably propose.

  • Steering Committee Each Party shall name a mutually agreed upon equal number of representatives for the Steering Committee, which shall meet twice per calendar year, or as otherwise mutually agreed by the Parties. In the event that a Steering Committee dispute cannot be resolved, such dispute shall be escalated to a senior executive of each of Customer and Lonza. The primary function of the Steering Committee is to ensure the ongoing communication between the Parties and discuss and resolve any issues arising under this Agreement. In addition to the primary function described above, the Steering Committee shall also take on the following responsibilities:

  • Investment Committee The board of directors of the insurance company shall appoint an investment committee of the investment manager as the investment committee of the insurance company. The investment committee shall meet at least once each quarter to review the investments and loans of the insurance company.

  • Joint Steering Committee [***] following the Effective Date [***], a joint steering committee (the “JSC”) will be established by the Parties to provide oversight and to facilitate information sharing between the Parties with respect to the activities under this Agreement.

Time is Money Join Law Insider Premium to draft better contracts faster.